The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Pharmacokinetic variability of anticancer agents
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985
Goycoolea, A. (1997) · Cited by 3,615
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
TAN, P. (2001) · A Clinical Approach to Medicine · doi:10.1142/9789810248178_0024 · Cited by 2,697
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,365
Epstein, F. H., Brenner, B. M., Meyer, T. W., & Hostetter, T. H. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209093071104 · Cited by 2,075
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Self-citationJin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., Collins, J. L., & Kliewer, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130155097 · Cited by 947
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
Kartner, N., Evernden-Porelle, D., Bradley, G., & Ling, V. (1985) · Nature · doi:10.1038/316820a0 · Cited by 908
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 870
Beutler, E., Gelbart, T., & Demina, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8170 · Cited by 853
Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines
Riordan, J. R., Deuchars, K., Kartner, N., Alon, N., Trent, J., & Ling, V. (1985) · Nature · doi:10.1038/316817a0 · Cited by 826
Cascorbi, I. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114164 · Cited by 747
Noncompartmental Determination of the Steady‐State Volume of Distribution
Benet, L. Z., & Galeazzi, R. L. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600680845 · Cited by 735
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile.
Heggie, G. D., Sommadossi, J., Cross, D. S., Huster, W. J., & Diasio, R. B. (1987) · PubMed · Cited by 722
Brenner, R. J., Spring, D. B., Sebastian, A., McSherry, E. M., Genant, H. K., Palubinskas, A. J., & Morris, R. C. (1982) · New England Journal of Medicine · doi:10.1056/nejm198207223070403 · Cited by 700
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.
Roninson, I. B., Chin, J. E., Choi, K. G., Gros, P., Housman, D. E., Fojo, A., Shen, D. W., Gottesman, M. M., & Pastan, I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4538 · Cited by 686
Cancer burden in the aged: an epidemiologic and demographic overview.
Yancik, R. (1997) · PubMed · Cited by 558
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., & Watkins, P. B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116064 · Cited by 528
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
de Waziers, I., Cugnenc, P. H., Yang, C. S., Leroux, J. P., & Beaune, P. H. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12474-9 · Cited by 502
Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., & Guzelian, P. S. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113156 · Cited by 480
Cancer burden in the aged: An epidemiologic and demographic overview
Yancik, R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971001)80:7<1273::aid-cncr13>3.0.co;2-4 · Cited by 473
Effects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457
Imai, Y., Nakane, M., Kage, K., Tsukahara, S., Ishikawa, E., Tsuruo, T., Miki, Y., & Sugimoto, Y. (2002) · PubMed · Cited by 442
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines
Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.488 · Cited by 428
First-pass metabolism of cyclosporin by the gut
Kolars, J. C., Watkins, P. B., Merion, R. M., & Awni, W. M. (1991) · The Lancet · doi:10.1016/0140-6736(91)92302-i · Cited by 422
Sotaniemi, E. A., Arranto, A. J., Pelkonen, O., & Pasanen, M. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90166-1 · Cited by 415
Grochow, L. B., Jones, R. J., Brundrett, R. B., Braine, H. G., Chen, T.-L., Saral, R., Santos, G. W., & Colvin, O. M. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00694339 · Cited by 404
Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).
Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., & Vandenbranden, M. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09441-6 · Cited by 402
Wils, J., Klein, H. O., Wagener, D. J. T., Bleiberg, H., Reis, H. E., Korsten, F. W., Conroy, T., Fickers, M. M. F., Leyvraz, S., & Buyse, M. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.827 · Cited by 388
Hitzl, M., Drescher, S., van der Kuip, H., Schäffeler, E., Fischer, J., Schwab, M., Eichelbaum, M., & Fromm, M. F. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00003 · Cited by 374
Substrates of human hepatic cytochrome P450 3A4
Li, A. (1995) · Toxicology · doi:10.1016/0300-483x(95)03155-9 · Cited by 367
CYP3A gene expression in human gut epithelium
Kolars, J. C., Lown, K. S., Schmiedlin-Ren, P., Ghosh, M., Fang, C., Wrighton, S. A., Merion, R. M., & Watkins, P. B. (1994) · Pharmacogenetics · doi:10.1097/00008571-199410000-00003 · Cited by 365
Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.
Wei, X., McLeod, H. L., McMurrough, J., Gonzalez, F. J., & Fernandez-Salguero, P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118830 · Cited by 356
Pharmacokinetic/Pharmacodynamic Modeling in Drug Development
Sheiner, L. B., & Steimer, J.-L. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.67 · Cited by 351
Effects of aging on the renal glomerulus
Anderson, S., & Brenner, B. M. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90718-7 · Cited by 346
Slattery, J. T., Sanders, J. E., Buckner, C. D., Schaffer, R. L., Lambert, K. W., Langer, F. P., Anasetti, C., Bensinger, W., Fisher, L. D., & Appelbaum, F. R. (1995) · PubMed · Cited by 343
Characterization of Human Small Intestinal Cytochromes P-450
Zhang, Q.-Y., Dunbar, D., Ostrowska, A., Zeisloft, S., Yang, J., & Kaminsky, L. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15229-4 · Cited by 343
Kivisto, K., Kroemer, H., & Eichelbaum, M. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05796.x · Cited by 340
Association of busulfan area under the curve with veno-occlusive disease following BMT.
Dix, S. P., Wingard, J. R., Mullins, R. E., Jerkunica, I., Davidson, T. G., Gilmore, C. E., York, R., Lin, L., Devine, S. M., Geller, R. B., et al. (1996) · PubMed · Cited by 311
Watkins, P. B., Wrighton, S. A., Barnett, J. L., Lown, K. S., Kunze, K. L., Thummel, K. E., & Kolars, J. C. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/n8xg-qs69 · Cited by 304
Ranson, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.13.1074 · Cited by 303
Oral chemotherapy: rationale and future directions.
DeMario, M. D., & Ratain, M. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2557 · Cited by 293
Self-citationRole of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
Baker, S. D., Verweij, J., Rowinsky, E. K., Donehower, R. C., Schellens, J. H. M., Grochow, L. B., & Sparreboom, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1883 · Cited by 286
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
Milano, G., Etienne, M. C., Pierrefite, V, Barberi-Heyob, M., Deporte-Fety, R., & Renée, N. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690098 · Cited by 275
Zamber, C. P., Lamba, J. K., Yasuda, K., Farnum, J., Thummel, K., Schuetz, J. D., & Schuetz, E. G. (2003) · Pharmacogenetics · doi:10.1097/00008571-200301000-00004 · Cited by 272
Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines
Lopes, N. M., Adams, E. G., Pitts, T. W., & Bhuyan, B. K. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685842 · Cited by 271
Kurata, Y., Ieiri, I., Kimura, M., Morita, T., Irie, S., Urae, A., Ohdo, S., Ohtani, H., Sawada, Y., Higuchi, S., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126177 · Cited by 269
A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation
Bruno, R., Vivier, N., Vergniol, J. C., De Phillips, S. L., Montay, G., & Sheiner, L. B. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353487 · Cited by 265
GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE
Wells, P. G., Mackenzie, P. I., Roy Chowdhury, J., Guillemette, C., Gregory, P. A., Ishii, Y., Hansen, A. J., Kessler, F. K., Kim, P. M., Roy Chowdhury, N., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.281 · Cited by 260
Kuilenburg, A. B. P., Muller, E. W., Haasjes, J., Meinsma, R., Zoetekouw, L., Waterham, H. R., Baas, F., Richel, D. J., & Gennip, A. H. (2001) · PubMed · Cited by 253
Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds.
Ho, P.-C., Saville, D. J., & Wanwimolruk, S. (2001) · PubMed · Cited by 234
Raida, M., Schwabe, W., Häusler, P., Kuilenburg, A. B. P., Gennip, A. H., Behnke, D., & Höffken, K. (2001) · PubMed · Cited by 231
Johnson, M. R., Hageboutros, A., Wang, K., High, L. B., Smith, J. B., & Diasio, R. B. (1999) · PubMed · Cited by 225
Slaviero, K. A., Clarke, S. J., & Rivory, L. P. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01034-9 · Cited by 224
Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism.
Shedlofsky, S. I., Israel, B. C., McClain, C. J., Hill, D. B., & Blouin, R. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117582 · Cited by 221
The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
Mancinelli, L. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113183 · Cited by 206
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Terwogt, J. M. M., Malingré, M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M., & Schellens, J. H. M. (1999) · PubMed · Cited by 205
van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A., Borst, P., Nooijen, W., & Beijnen, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.530 · Cited by 202
ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2
Kerb, R., Hoffmeyer, S., & Brinkmann, U. (2001) · Pharmacogenomics · doi:10.1517/14622416.2.1.51 · Cited by 202
Burk, O., Koch, I., Raucy, J., Hustert, E., Eichelbaum, M., Brockmöller, J., Zanger, U. M., & Wojnowski, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404949200 · Cited by 198
Vestal, R. E. (1997) · Cancer · Cited by 189
Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., Ishikawa, T., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5850 · Cited by 189
Ito, K.-I., Olsen, S. L., Qiu, W., Deeley, R. G., & Cole, S. P. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011246200 · Cited by 166
Chu, X.-Y., Kato, Y., Niinuma, K., Sudo, K.-I., Hakusui, H., & Sugiyama, Y. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36601-7 · Cited by 161
Gardner-Stephen, D., Heydel, J.-M., Goyal, A., Lu, Y., Xie, W., Lindblom, T., Mackenzie, P., & Radominska-Pandya, A. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.340 · Cited by 160
Mantovani, G., Macciò, A., Lai, P., Massa, E., Ghiani, M., & Santona, M. C. (1998) · PubMed · Cited by 158
Predictors of tolerance to chemotherapy in older cancer patients
Extermann, M., Chen, H., Cantor, A. B., Corcoran, M. B., Meyer, J. S., Grendys, E. C., Cavanaugh, D., Antonek, S., Camarata, A., Haley, W. E., et al. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00090-4 · Cited by 157
Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues.
McKinnon, R. A., Burgess, W. M., Hall, P. M., Roberts‐Thomson, S. J., Gonzalez, F. J., & McManus, M. E. (1995) · Gut · doi:10.1136/gut.36.2.259 · Cited by 155
Exposure‐Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice
Veronese, M. L., Gillen, L. P., Burke, J., et al. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003256059 · Cited by 149
Murray, G. I., Barnes, T., Hf, S., Ewen, S. W. B., Melvin, W., & Burke, M. D. (1988) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1988.tb03331.x · Cited by 147
Bleyzac, N., Souillet, G., Magron, P., Janoly, A., Martin, P., Bertrand, Y., Galambrun, C., Dai, Q., Maire, P. H., Jelliffe, R. W., et al. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703207 · Cited by 143
Influence of Race or Ethnicity on Pharmacokinetics of Drugs
Johnson, J. A. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9702168 · Cited by 142
Potential of chemotherapy?herb interactions in adult cancer patients
McCune, J. S., Hatfield, A. J., Blackburn, A. A. R., Leith, P. O., Livingston, R. B., & Ellis, G. K. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-004-0598-1 · Cited by 138
Saito, S., Iida, A., Sekine, A., Miura, Y., Ogawa, C., Kawauchi, S., Higuchi, S., & Nakamura, Y. (2002) · Journal of Human Genetics · doi:10.1007/s100380200018 · Cited by 135
The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels
Kerb, R., Aynacioglu, A. S., Brockmöller, J., Schlagenhaufer, R., Bauer, S., Szekeres, T., Hamwi, A., Fritzer-Szekeres, M., Baumgärtner, C., Ongen, H. Z., et al. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500025 · Cited by 135
Cullinan, S. A., Moertel, C. G., Wieand, H. S., O'Connell, M. J., Poon, M. A., Krook, J. E., Mailliard, J. A., & Tschetter, L. K. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.412 · Cited by 134
Woo, J. S., Lee, C. H., Shim, C. K., & Hwang, S. (2003) · Pharmaceutical Research · doi:10.1023/a:1022286422439 · Cited by 133
Co-administration of cyclosporin enables oral therapy with paclitaxel
Terwogt, J. M. M., Beijnen, J. H., Huinink, W. W. T. B., Rosing, H., & Schellens, J. H. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)24030-x · Cited by 129
Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients
Baker, S. D., van Schaik, R. H. N., Rivory, L. P., ten Tije, A. J., Dinh, K. L., Graveland, W. J., Schenk, P. W., Charles, K. A., Clarke, S. J., Carducci, M. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1371 · Cited by 125
Pharmacogenomics of the OATP and OAT Families
Marzolini, C., Tirona, R. G., & Kim, R. B. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.273.29831 · Cited by 124
Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W. J., Schellens, J. H. M., & van Tellingen, O. (2000) · PubMed · Cited by 121
Lindholm, A., Welsh, M. S., Alton, C., & Kahan, B. D. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.156 · Cited by 120
Iida, A., Saito, S., Sekine, A., Mishima, C., Kitamura, Y., Kondo, K., Harigae, S., Osawa, S., & Nakamura, Y. (2002) · Journal of Human Genetics · doi:10.1007/s100380200041 · Cited by 120
Pharmacology of Cancer Chemotherapy in the Older Person
Baker, S. D., & Grochow, L. B. (1997) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30188-5 · Cited by 119
Phase I and Pharmacokinetic Study of Oral Paclitaxel
Malingré, M. M., Terwogt, J. M. M., Beijnen, J. H., Rosing, H., Koopman, F. J., van Tellingen, O., Duchin, K., Huinink, W. W. T. B., Swart, M., Lieverst, J. A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2468 · Cited by 96
Yamamoto, N., Tamura, T., Kamiya, Y., Sekine, I., Kunitoh, H., & Saijo, N. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2301 · Cited by 93
Role of red blood cells in pharmacokinetics of chemotherapeutic agents
Schrijvers, D. L. A. L., Bruyn, E. D., van Oosterom, A. T., & Vermorken, J. B. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199902000-00002 · Cited by 93
Cytochromes P-450 in the intestinal mucosa of man
Peters, W. H. M., & Kremers, P. G. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90194-9 · Cited by 90
Noncompartmental Versus Compartmental Modelling in Clinical Pharmacokinetics
Gillespie, W. R. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199120040-00001 · Cited by 89
Noncompartmental vs. compartmental analysis: some bases for choice
DiStefano, J. J. (1982) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1982.243.1.r1 · Cited by 89
The randomized concentration-controlled trial: An evaluation of its sample size efficiency
Sanathanan, L. P., & Peck, C. C. (1991) · Controlled Clinical Trials · doi:10.1016/0197-2456(91)90041-j · Cited by 87
Polypharmacy in the Older Patient With Cancer.
Me, C. (1997) · PubMed · Cited by 86
Yamamoto, N., Tamura, T., Murakami, H., Shimoyama, T., Nokihara, H., Ueda, Y., Sekine, I., Kunitoh, H., Ohe, Y., Kodama, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.036 · Cited by 86
Tateishi, T., Watanabe, M., Moriya, H., Yamaguchi, S., Sato, T., & Kobayashi, S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00375-x · Cited by 83
Hayward, M. A., Brock, M. L., & Shapiro, D. J. (1982) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1982.243.1.e1 · Cited by 82
The role of estrogen receptor in Xenopus laevis vitellogenin gene expression
Hayward, M. A., Brock, M. L., & Shapiro, D. J. (1982) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1982.243.1.c1 · Cited by 81
Pharmacokinetic Optimisation of Cancer Chemotherapy
Masson, E., & Zamboni, W. C. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732040-00005 · Cited by 76
Pierelli, L., Perillo, A., Greggi, S., Salerno, G., Panici, P. B., MENICHELLA, G., Fattorossi, A., Leone, G. G. M., Mancuso, S., & Scambia, G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1288 · Cited by 76
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
Gupta, E., Safa, A. R., Wang, X., & Ratain, M. J. (1996) · PubMed · Cited by 75
Self-citationAge-Related Changes in the Gastrointestinal System
Iber, F. L., Murphy, P. A., & Connor, E. S. (1994) · Drugs & Aging · doi:10.2165/00002512-199405010-00004 · Cited by 74
Smorenburg, C. H., Sparreboom, A., Bontenbal, M., Stoter, G., Nooter, K., & Verweij, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.058 · Cited by 74
A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer
Williams, M. L., Bhargava, P., Cherrouk, I., Marshall, J. L., Flockhart, D. A., & Wainer, I. W. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00189.x · Cited by 73
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
Alberts, D. S., & Dorr, R. T. (1998) · The Oncologist · doi:10.1634/theoncologist.3-1-15 · Cited by 72
Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer
Socinski, M. A. (1999) · The Oncologist · doi:10.1634/theoncologist.4-5-408 · Cited by 71
Cancer pharmacology in the elderly.
Egorin, M. J. (1993) · PubMed · Cited by 68
Polypharmacy in the Older Patient with Cancer
Corcoran, M. E. (1997) · Cancer Control · doi:10.1177/107327489700400505 · Cited by 67
Pharmacokinetic Considerations of Oral Chemotherapy in Elderly Patients with Cancer
Skirvin, J. A., & Lichtman, S. M. (2002) · Drugs & Aging · doi:10.2165/00002512-200219010-00003 · Cited by 62
Kruijtzer, C. M. F., Schellens, J. H. M., Mezger, J. M., Scheulen, M. E., Keilholz, U., Beijnen, J. H., Rosing, H., Mathôt, R. A. A., Marcus, S., van Tinteren, H., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.058 · Cited by 59
Usefulness of the Two-Compartment Open Model in Pharmacokinetics
Metzler, C. M. (1971) · Journal of the American Statistical Association · doi:10.1080/01621459.1971.10482216 · Cited by 50
Chester, J. D., Joel, S. P., Cheeseman, S. L., Hall, G. D., Braun, M. S., Perry, J., Davis, T., Button, C. J., & Seymour, M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.049 · Cited by 50
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer
Kruijtzer, C. M. F., Boot, H., Beijnen, J. H., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg078 · Cited by 47
Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
Fanucchi, M. P., Walsh, D., Fleisher, M., Lokos, G., Williams, L., Cassidy, C., Vidal, P., Chou, T., Niedzwiecki, D., & Young, C. W. (1987) · PubMed · Cited by 39
A population model of epirubicin pharmacokinetics and application to dosage guidelines
Ralph, L. D., Thomson, A. H., Dobbs, N. A., & Twelves, C. J. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0608-x · Cited by 31
Pharmacokinetic studies in cancer chemotherapy: Usefulness in clinical practice
Freyer, G., Ligneau, B., Tranchand, B., Ardiet, C. J., Serre-Debeauvais, F., & Trillet-Lenoir, V. N. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90036-0 · Cited by 26
Cited by
Nebert, D. W., & Dalton, T. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2015 · Cited by 958
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
Circadian Rhythms: Mechanisms and Therapeutic Implications
Levi, F., & Schibler, U. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105208 · Cited by 645
Lipid nanocapsules: A new platform for nanomedicine
Huynh, N. T., Passirani, C., Saulnier, P., & Benoit, J. P. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.026 · Cited by 595
Metadata
- Authors
- Undevia, S. D., Gomez-Abuin, G., & Ratain, M. J.
- Venue
- Nature Reviews Cancer
- Published
- 2005-06-01
- Volume
- 5
- Issue
- 6
- Pages
- 447-458
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2043707675
- Cited by
- 258
- References
- 125
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.